Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
Journal of the European Academy of Dermatology and Venereology Sep 01, 2017
Lear JT, et al. – The intent here was to inspect the long–term efficacy and safety profile of sonidegib in locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC) in the BOLT 18– and 30–month analyses. A long–term efficacy and safety were illustrated by sonidegib in the study cohort. Hence, the findings recommended the use of sonidegib 200 mg per local treatment guidelines.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
